The preventive treatment of migraine

Neurologist

Volumn 12, Issue 4, 2006, Pages 204-213

  Bigal, Marcelo E ^a,b,c,d   Lipton, Richard B ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Migraine prevention; Preventive treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; DOXEPIN; FLUNARIZINE; FLUOXETINE; GABAPENTIN; MAGNESIUM; METOPROLOL; MIRTAZAPINE; NIMODIPINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROPRANOLOL DERIVATIVE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIMOLOL; TOPIRAMATE; UBIDECARENONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ANXIETY; ASTHENIA; BLURRED VISION; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG MISUSE; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPOTENSION; IMPOTENCE; INCREASED APPETITE; INDIGESTION; INJECTION SITE PAIN; IRRITABILITY; LIVER DYSFUNCTION; LIVER TOXICITY; MIGRAINE; MORBIDITY; MUSCLE DISEASE; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREMOR; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CENTRAL NERVOUS SYSTEM AGENTS; COMPLEMENTARY THERAPIES; HUMANS; MIGRAINE DISORDERS; PERIPHERAL NERVOUS SYSTEM AGENTS;

EID: 33746568433     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000219666.65101.a9     Document Type: Review

References (79)

1. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, ed. Epidemiology of Pain. Seattle: IASP Press; 1999:159-170.
2. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity: disability, pain intensity, and attack frequency and duration. Neurology. 1994; 44(suppl 4):24-39.
3. Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. New York: Oxford University Press; 2001:85-107.
4. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346:257-270.
5. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache. 1998;38:87-96.
6. Lipton RB, Diamond D, Freitag F, et al. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2005;45:792.
7. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
8. Silberstein SD, Lipton RB. The preventive treatment of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. New York, NY: Oxford University Press; 2001:200-245.
9. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29-35.
10. Steiner TJ, Scher AL, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23:519-527.
11. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
12. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;12:290: 2443-2454.
13. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23: 429-440.
14. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology. 2000;54:1553.
15. Silberstein SD, Diamond D, Freitag F, et al. The epidemiology of migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2005;45:795.
16. Silberstein SD, Goadsby PJ. Migraine: a preventive treatment. Cephalalgia. 2002;22:491-512.
17. Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther. 2004;11:130-140.
18. Holroyd KA, Penzien DB, Coordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991; 31:333-340.
19. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695-699.
20. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973;36:684-690.
21. Markley HG, Gasser PA, Markley ME, et al. Fluoxetine in prophylaxis of migraine: clinical experience. Cephalalgia. 1991;11:164-165.
22. Solomon G, Kunkel R. Effects of fluoxetine on premenstrual syndrome in chronic headache sufferers. Headache. 1990;30:301.
23. Tollefson GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry. 1983;44:280-288.
24. Gawel MJ, Kreeft J, Nelson RF, et al. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci. 1992;19:340-345.
25. Ansell E, Fazzone T, Festenstein R, et al. Nimodipine in migraine prophylaxis. Cephalalgia. 1988;8:269-272.
26. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache. 1989;29:633-638.
27. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol. 1997;54:1141-1145.
28. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis: for the Depakote ER Migraine Study Group. Neurology. 2003;58:1652-1659.
29. Mathew NT, Rapoport AM, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-128.
30. Silberstein SD, Neto W, Schmitt J, et al; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490-495.
31. Brandes JL, Saper JR, Diamond M, et al; MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965-973.
32. Silberstein SD. Topiramate in migraine prevention. Headache. 2005; 45(suppl 1):S57-65.
33. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia. 1994;14:328-329.
34. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50:466-470.
35. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44:885-890.
36. Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulfate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci. 1995;89:633-636.
37. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: a double-blind placebo-controlled study. Cephalalgia. 1996;16:436-440.
38. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257-263.
39. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298-301.
40. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [American Academy of Neurology Web site]. Available at: http://www.aan.com/professionals/practice/pdfs/g10090.pdf. Accessed July 4, 2005.
41. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther. 2000;38:430-435.
42. Lipton RB, Göbel H, Einhäupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240-2244.
43. Montagna P, Cortelli P, Barbiroli B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia. 1994;14:184-193.
44. 31P NMR spectroscopy alterations in migraine patients. J Neurol Sci. 1991;104:182-189.
45. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22:137-141.
46. Sandor PS, Di Clemente L, Copploa G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713-715.
47. De Weert CJ, Bootsma HPR, Henriks H. Herbal medicine in migraine prevention. Phytomedicine. 1996;3:225-230.
48. Pfaffenrath V, Diener HC, Fischer M, et al; Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22:523-532.
49. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123:669-676.
50. Zwart JA, Bovim G, Sand T, et al. Tension headache: botulinum toxin paralysis of temporal muscles. Headache. 1994;34:458-462.
51. Relja MA. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol. 1997;4(suppl 2):71-72.
52. Tepper SJ, Bigal ME, Sheftell FD, et al. Botulin toxin type a in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004;44:794-800.
53. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-43.
54. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment: for the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445-450.
55. Dodick DW, Mauskop A, Elkind AH, et al; BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45:315-324.
56. Krusz JC. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia. 2001;21:373.
57. Drake ME, Greathouse NI, Armentbright AD, et al. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia. 2001;21:373.
58. Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res. 2005;66:212-221.
59. Drake ME, Greathouse NI, Armentbright AD, et al. Preventive treatment of migraine with zonisamide [abstract]. Cephalalgia. 2001;21:374.
60. Krusz JC. Zonisamide in the treatment of headache disorders [abstract]. Cephalalgia. 2001;21:374-375.
61. Saper JR, Winner PK, Lake AE. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache. 2001;41:357-368.
62. Lake AE, Saper JR, Spiering EL, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, multicenter outcome study [abstract]. Headache. 2002;42:430.
63. Saper JR, Lake AE, Tepper SJ. Nefazadone for chronic daily headache prophylaxis: an open-label study. Headache. 2001;111:465-474.
64. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin converting enzyme. Clin Exc Hypertens A. 1987;9:243-259.
65. Paterna S, DiPasquale P, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133-136.
66. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
67. Sawynok J, Sweeney MI, White TD. Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br J Pharmacol. 1986;88:923-930.
68. Goadsby PJ, Hoskin KL, Storer RJ, et al. Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain. 2002;125:1392-1401.
69. Darland T, Grandy DK. The orphanin FQ system: an emerging target for the management of pain? Br J Anaesth. 1998;81:29-37.
70. Xu X, Grass S, Hao J, et al. Nociceptin/orphanin FQ in spinal nociceptive mechanisms under normal and pathological conditions. Peptides. 2000;21:1031-1036.
71. Hou M, Uddman R, Tajti J, et al. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett. 2002;330:223-226.
72. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia. 2004;24:596-602.
73. Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS Clinical Proof of Concept Study Group: calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104-1110.
74. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493-494.
75. Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629-637.
76. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427-434.
77. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81-89.
78. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology. 2004;63:2022-2027.
79. Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology. 2003;60:1366-1368.